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Poster Session I 101recommendations is often expensive and they take little account of
geographical variance in the incidence of such organisms.
The Wellington Transplant Unit has historically had a very low
incidence of fungal infections. Recently the unit has been exposed to
major dust contamination from building demolition and rebuilding
on the hospital campus. To obviate this threat the transplant unit
has nursed patients in newly commissioned HEPA filtered rooms.
This project has been prospectively monitored with environmental
surveillance cultures and recording of patient infections. Data will
be presented showing a very low environmental contamination
and a low patient infection rate. This challenges the universal rec-
ommendation for the need for protected rooms. This conclusion
is further supported by a care model that emphasises early patient
discharge to a day care unit which does not have protected rooms.274
LEVOFLOXACINE ANTIBACTERIAL PROPHYLAXIS FOR PATIENTS
TREATED WITH HIGH DOSE CHEMOTHERAPY AND AUTOLOGOUS
STEM CELL TRANSPLANTATION
Casas, C.P., Abello, V., Rosales, C., Pedraza, E., Esguerra, H.,
Linares, A., Rosales, M.L. Clınica de Marly, Bogota, Colombia.
Bacterial infections are a major cause of morbility and mortality
in neutropenic patients after high dose chemotherapy. We per-
formed a retrospective analysis to compare results before and after
instituting a prophylactic antibacterial regimen with Levofloxacine,
in patients undergoing an auto-SCT.
Here we analyze data for patients transplanted from July 2006
and June 2007 (group A), who received Levofloxacine as antibacte-
rial prophylaxis and compared the results with a control group
transplanted from July 2005 to June 2006 (group B), who didn’t re-ceive Levofloxacine. Both groups received similar conditioning reg-
imens and support treatment.
Indication for auto-SCTwereHodgkin Lymphoma, NonHodg-
kin Lymphoma, Multiple Myeloma and Acute Myeloid Leukemia.
There were 36 patients in group A and 24 in group B. Table 1 com-
pares the results in both groups.
In this series of 84 patients, Levofloxacine prophylaxis reduced
the percentage of patients with fever, hospital stay, days of neutro-
penic fever, days of antibiotic uses, number of antibiotics per pa-
tient, % of patient receiving antimicotics. This results are in
accordance with recent publish papers on that subject.Characteristics of patients by groups
Characteristis Group A Group B# Patients 36 24
Age (years)* 44 (12–67) 35.1 (6–68)
M/F 22/14 18/6
Hospital Stay (days)* 23 (14–37) 27 (16–44)
% patients with fever 69.4% 95.8%
Neutropenic fever
(days)*3.6 5.3Antibiotic use (days)* 18 (0–69) 27 (4–77)
Number antibiotics/
patient*2.3 (0–6) 3.4 (1–6)% patients treated with
antimicotics27% 50%Mortality before day 30 0/36 2/24*Mean (range).
